TNG-908 is a small molecule commercialized by Tango Therapeutics, with a leading Phase II program in Squamous Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of TNG-908’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for TNG-908 is expected to reach an annual total of $55 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
TNG-908 Overview
TNG-908 is under development for the treatment of MTAP-deleted cancers like cholangiocarcinoma, mesothelioma, squamous and non squamous non-small cell lung cancer, bladder cancer, malignant peripheral nerve sheath tumor (MPNST) glioblastoma multiforme, colon cancer and soft tissue sarcoma. It is administered through oral route. It acts by targeting the protein arginine methyltransferase 5 (PRMT5) enzyme.
See Also:
Tango Therapeutics Overview
Tango Therapeutics is a biotechnology company that discovers and develops novel drug targets for the treatment of cancer. The company is investigating TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) against methylthioadenosine phosphorylase (MTAP) deleted cancers. It also develops PRMT5 TNG462 for MTAP-deleted tumors; CoREST TNG260 for STK11-mutant cancers; USP1 TNG348 for BRCA1 and BRCA2-mutant and HRD+ cancers. It works in collaboration with Gilead Sciences to discover, develop, and commercialize cancer therapies. Tango Therapeutics is headquartered in Boston, Massachusetts, the US.
The company reported revenues of (US Dollars) US$24.9 million for the fiscal year ended December 2022 (FY2022), a decrease of 32.9% over FY2021. The operating loss of the company was US$111.1 million in FY2022, compared to an operating loss of US$58.2 million in FY2021. The net loss of the company was US$108.2 million in FY2022, compared to a net loss of US$58.2 million in FY2021.
The company reported revenues of US$10.7 million for the third quarter ended September 2023, a decrease of 26.5% over the previous quarter.
For a complete picture of TNG-908’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
